Publication date: May 23, 2021
The study evaluated over 10,000 patients across 31 cancer types who had available data in The Cancer Genome Atlas (TCGA). -While TMB status does show value in predicting response to immune checkpoint blockade in several cancer types, this was not generalizable across all cancers. The KEYNOTE-158 trial included patients with small cell lung cancer, cervical, endometrial, anal, vulvar, neuroendocrine, salivary, and thyroid cancers, as well as mesothelioma. In addition, the study found that the F1CDx assay overestimated TMB-H cancer-related genes compared with TMB from whole-exome sequencing data in 25 of 31 cancer types analyzed. Moreover, a negative correlation was observed between the median TMB in a given cancer type and the degree of TMB-H overestimation. As such, evaluating whether TMB-H could serve as a predictive biomarker in the latter subgroup was relevant to a large proportion of patients. Samples were categorized by whether CD8 T-cell infiltration positively correlated with neoantigen load.
|disease||MESH||small cell lung cancer|
|pathway||KEGG||Small cell lung cancer|